Congress expands Medicaid for sickle cell patients with guaranteed dental, vision care

What it does

This bill allows states to create specialized Medicaid health home programs specifically for people with sickle cell disease, starting January 1, 2026. These programs must include dental and vision services (even if the state doesn't normally cover them for other Medicaid patients), and states must report on care quality, access, and costs after two years. The federal government will publish best practices to help states design these programs.

Why we flagged it

The bill creates a new Medicaid benefit pathway for a specific disease population, mandating integrated care and dental/vision coverage. It is a straightforward public-health measure with no hidden provisions or narrow beneficiaries.

What the text implies

• Dental and vision coverage mandate may create state budget pressure if enrollment exceeds projections, potentially affecting state Medicaid solvency or requiring federal cost-sharing negotiation.
• Health home model concentrates care coordination authority with states; variation in implementation quality across states could create disparities in outcomes for the same disease.
• Reporting requirements (quality, access, expenditure) establish a precedent for disease-specific Medicaid accountability that could be extended to other chronic conditions, reshaping Medicaid program structure.

Who it affects

Sickle cell disease patients—a population that is disproportionately Black and historically underserved—gain dedicated care coordination, guaranteed dental and vision coverage, and structured accountability for outcomes. The bill creates no new costs for patients and expands Medicaid coverage without narrowing it for others.

Who stands to gain

• Medicaid managed care organizations
• Health home service providers
• Dental and vision care providers
• Pharmaceutical companies (sickle cell therapeutics)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), State Medicaid programs, Sickle Cell Disease patient advocacy organizations, Medical specialty societies, Merck (MRK) — semantic affinity via sickle cell therapeutics

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Feb 25, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 25, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 9 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $910,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

Cory Booker, the sponsor, reported $496,300 in PAC receipts in the 2026 cycle.

• American Psychological Association Services Inc.(fka American Psychological Assn — $340,000 on 1 filing
• National Marrow Donor Program — $280,000 on 1 filing
• American Society of Hematology — $130,000 on 2 filings
• American Society of Hematology — $80,000 on 2 filings
• Sick Cells — $60,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.